Katherine Baicker Elected to Lilly Board of Directors

Katherine Baicker Elected to Lilly Board of Directors
 

INDIANAPOLIS, Dec. 12, 2011 /PRNewswire/ -- Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Katherine Baicker, Ph.D. as a new member, effective December 12, 2011. Baicker, 40, is Professor of Health Economics in the Department of Health Policy and Management at the Harvard School of Public Health. She is also a research associate at the National Bureau of Economic Research and an elected member of the Institute of Medicine. As a member of Lilly's board, Professor Baicker will serve on the public policy and compliance committee. She will serve under interim election and will stand for election by Lilly shareholders at the company's annual meeting in April, 2012.

"I am very pleased to welcome Kate Baicker to the Lilly board. Her experience and expertise will surely benefit Lilly shareholders and the patients we serve," commented John Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "Kate is a leading researcher in the fields of health economics, public economics and labor economics. As a valued advisor to numerous healthcare-related commissions and committees, her expertise in healthcare policy and healthcare delivery is recognized by both academia and government. In a rapidly-changing healthcare landscape, Kate's insights will be invaluable as we work to sustain an environment that is conducive to medical innovation while still ensuring access to affordable, quality healthcare."

Professor Baicker's research focuses primarily on the factors that drive the distribution, generosity, and effectiveness of public and private health insurance, with a particular focus on health insurance finance and the effect of reforms on the distribution and quality of care.  Her research has been published in journals such as Health Affairs, the Journal of Public Economics, and the Quarterly Journal of Economics, and has been featured in the New York Times, the Wall Street Journal, Business Week, and on National Public Radio.  She is currently one of the leaders of a research program investigating the many effects of expanding health insurance coverage in the context of a randomized Medicaid expansion in Oregon.

Prior to her current position at the Harvard School of Public Health, Professor Baicker served as a Senate-confirmed Member of the President's Council of Economic Advisers from 2005 - 2007, where she played a leading role in the development of health policy.  She currently serves on the Editorial Boards of Health Affairs, the Journal of Health Economics, and the Forum for Health Economics and Policy; as Vice Chair of the Board of Directors of AcademyHealth; on the Congressional Budget Office's Panel of Health Advisers; and as a Commissioner on the Medicare Payment Advisory Commission.

About Lilly 
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


SOURCE Eli Lilly and Company
Back to top
RELATED LINKS
http://www.lilly.com

 

 

 

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.